SuperworthEditas Medicine EDIT
- Market cap
- $368.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $47M
- +21% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −32.7%
Editas Medicine trades at 7.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $47M over the last twelve months, up 21% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.3M+12605% | $60M+819% | $1.1M−89% | $513K−82% | $61K−99% | $30.6M−49% | $4.7M+310% | $3.6M+598% | $7.5M+12266% | $24.7M−19% | $2.8M−39% | $11.9M+232% | |
| R&D | $40.5M−2% | $69.6M+34% | $48.8M+29% | $54.2M+82% | $47.6M+18% | $48.6M−30% | $26.6M−46% | $16.2M−70% | $19.8M−59% | $27.4M−44% | $17.6M−34% | $20.2M+25% |
| SG&A | $15M−8% | $14.5M−20% | $19.3M−16% | $18.2M+6% | $18.1M+21% | $16.4M+13% | $13.4M−31% | $12.9M−29% | $12.3M−32% | $11.4M−31% | $10.2M−24% | $11.6M−10% |
| −$50.2M−13% | −$24M−62% | −$67M+32% | −$71.9M+63% | −$65.7M+31% | −$46.6M+94% | −$76.2M+14% | −$51.5M−28% | −$24.5M−63% | −$7.8M−83% | −$25M−67% | −$18.6M−64% | |
| Interest expense | n/a | n/a | $0 | $0 | $0 | $2.2M | $2.2M | $2M | $2.4M | −$464K | $1.1M−52% | $1.1M−48% |
| Net income | −$45M−19% | −$18.9M−69% | −$62M+26% | −$67.6M+68% | −$62.1M+38% | −$45.4M+141% | −$76.1M+23% | −$53.2M−21% | −$25.1M−60% | −$5.6M−88% | −$25M−67% | −$18.2M−66% |
| −$0.55−32% | −$0.23−74% | −$0.76+7% | −$0.82+46% | −$0.75+36% | −$0.55+139% | −$0.92+21% | −$0.63−23% | −$0.28−63% | −$0.06−89% | −$0.26−72% | −$0.15−76% | |
| 81.6M+19% | 81.7M+19% | 81.9M+19% | 82.3M+15% | 82.5M+1% | 82.6M+1% | 83.1M+1% | 84.4M+3% | 90.1M+9% | 97.3M+18% | 97.9M+18% | 119.3M+41% |
EPS, diluted: 10 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q1 FY21 and Q2 FY21: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Editas Medicine's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EDITEditas Medicine | $368.6M | n/m | n/a | 7.8× | +21% | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
More on Editas Medicine
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .